ICON (ICLR) Hisse Özeti
Bir klinik araştırma kuruluşu olan ICON Public Limited Company, İrlanda'da, Avrupa'nın geri kalanında, Amerika Birleşik Devletleri'nde ve uluslararası alanda dış kaynaklı geliştirme ve ticarileştirme hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
ICLR Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.4% değerinin altında içsel indirim
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeICON Public Limited Company Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$125.00 |
| 52 Haftanın En Yüksek Seviyesi | US$211.00 |
| 52 Haftanın En Düşük Seviyesi | US$66.57 |
| Beta | 1.23 |
| 1 Aylık Değişim | 16.65% |
| 3 Aylık Değişim | -16.99% |
| 1 Yıllık Değişim | -9.73% |
| 3 Yıllık Değişim | -37.22% |
| 5 Yıllık Değişim | -44.96% |
| Halka arzdan bu yana değişim | 1,865.56% |
Son Haberler & Güncellemeler
Analiz Güncellemesi • May 06
ICLR: Site Network Expansion Will Support Recovery From Accounting Investigation
ICON's updated analyst price target has moved higher to $135.07 from $132.08 as analysts weigh recent target hikes and upgrades against ongoing accounting related concerns and more cautious growth assumptions. Analyst Commentary Street research on Icon reflects a split view, with some analysts focusing on valuation support and long term demand for clinical research, while others stay cautious around accounting risks and reduced earnings assumptions.Analiz Güncellemesi • Apr 22
ICLR: Oncology And Site Network Expansion Will Offset Accounting Overhang
ICON's updated analyst price target has shifted from about $142.86 to roughly $132.08 as analysts factor in lower modeled revenue growth, a slightly different discount rate, and a reduced future P/E, partly offset by a modestly higher profit margin outlook and mixed reactions to the recent accounting investigation and subsequent ratings changes. Analyst Commentary Recent research on ICON reflects a wide range of opinions as firms reassess the stock following the internal accounting investigation, reduced price targets, and updates to sector models in life science tools, diagnostics, and contract research organizations.
Analiz Güncellemesi • Apr 07
ICLR: Accounting Review And Backlog Uncertainty Will Pressure Earnings Quality And Sentiment
Narrative update on ICON analyst targets Analysts have collectively reset ICON's average price target lower to around $120, citing ongoing accounting investigations and reduced sector targets. Some also highlight the possibility of upside if biopharma activity improves and current valuation already reflects much of the perceived risk.Analiz Güncellemesi • Mar 24
ICLR: Accounting Investigation Will Drive Earnings Quality Concerns And Higher Perceived Risk
Narrative Update The analyst price target for ICON has been reset lower to $75.00 from $163.85 as analysts factor in higher perceived risk, more conservative growth and margin expectations, and sector wide target cuts following the company's internal accounting investigation and Q4 updates across life science tools and contract research peers. Analyst Commentary Recent Street research on ICON reflects a clear reset in expectations, with several firms cutting price targets and adjusting ratings following the internal accounting investigation and related uncertainty.Recent updates
Analiz Güncellemesi • May 06
ICLR: Site Network Expansion Will Support Recovery From Accounting Investigation
ICON's updated analyst price target has moved higher to $135.07 from $132.08 as analysts weigh recent target hikes and upgrades against ongoing accounting related concerns and more cautious growth assumptions. Analyst Commentary Street research on Icon reflects a split view, with some analysts focusing on valuation support and long term demand for clinical research, while others stay cautious around accounting risks and reduced earnings assumptions.Analiz Güncellemesi • Apr 22
ICLR: Oncology And Site Network Expansion Will Offset Accounting Overhang
ICON's updated analyst price target has shifted from about $142.86 to roughly $132.08 as analysts factor in lower modeled revenue growth, a slightly different discount rate, and a reduced future P/E, partly offset by a modestly higher profit margin outlook and mixed reactions to the recent accounting investigation and subsequent ratings changes. Analyst Commentary Recent research on ICON reflects a wide range of opinions as firms reassess the stock following the internal accounting investigation, reduced price targets, and updates to sector models in life science tools, diagnostics, and contract research organizations.Analiz Güncellemesi • Apr 07
ICLR: Accounting Review And Backlog Uncertainty Will Pressure Earnings Quality And Sentiment
Narrative update on ICON analyst targets Analysts have collectively reset ICON's average price target lower to around $120, citing ongoing accounting investigations and reduced sector targets. Some also highlight the possibility of upside if biopharma activity improves and current valuation already reflects much of the perceived risk.Analiz Güncellemesi • Mar 24
ICLR: Accounting Investigation Will Drive Earnings Quality Concerns And Higher Perceived Risk
Narrative Update The analyst price target for ICON has been reset lower to $75.00 from $163.85 as analysts factor in higher perceived risk, more conservative growth and margin expectations, and sector wide target cuts following the company's internal accounting investigation and Q4 updates across life science tools and contract research peers. Analyst Commentary Recent Street research on ICON reflects a clear reset in expectations, with several firms cutting price targets and adjusting ratings following the internal accounting investigation and related uncertainty.Analiz Güncellemesi • Mar 10
ICLR: Oncology Expansion Will Offset Accounting Overhang And Reset Sentiment
The updated analyst price target for ICON moves lower to $142.86 from $154.86, with analysts citing accounting-related uncertainty and potential backlog restatements, partially balanced by views that the recent selloff and current valuation may offer a more compelling risk and reward profile. Analyst Commentary Recent research on ICON reflects a split view, with some analysts seeing value after the selloff and others emphasizing ongoing accounting and growth risks.Analiz Güncellemesi • Feb 24
ICLR: Oncology Expansion And Accounting Overhang Are Expected To Reset Sentiment
Analysts have lowered their average price target on ICON from about $206 to roughly $155 as they factor in the ongoing internal accounting investigation, modestly softer growth and margin assumptions, a slightly higher discount rate, and a reduced future P/E multiple, even as some describe the recent share price weakness as creating a more compelling entry point. Analyst Commentary Recent research on ICON reflects a split view, with some analysts turning more constructive after the share price pullback while others remain cautious given the internal accounting investigation and softer growth and margin assumptions.Analiz Güncellemesi • Feb 09
ICLR: Oncology Expansion And Contract Visibility Will Support Future Upside Potential
Narrative Update on ICON Analysts have modestly adjusted their stance on ICON, with recent target changes clustered in a US$11 range. These changes reflect mixed views on softer revenue growth visibility, margin pressure into 2026, and updated healthcare utilization trends.Analiz Makalesi • Feb 06
It's Down 28% But ICON Public Limited Company (NASDAQ:ICLR) Could Be Riskier Than It Looks
ICON Public Limited Company ( NASDAQ:ICLR ) shares have had a horrible month, losing 28% after a relatively good period...Analiz Güncellemesi • Jan 25
ICLR: Mixed Margin And Cancellation Signals Will Shape Fairly Balanced Outlook
The analyst price target for ICON has edged higher by about US$1 to US$206.38, as analysts factor in slightly adjusted assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E after a mix of recent target raises and trims across the Street. Analyst Commentary Recent research on ICON reflects a split view, with some on the Street lifting targets while others are turning more cautious as they reassess growth, margins, and contract visibility heading into 2026.Analiz Güncellemesi • Jan 11
ICLR: Strong Bookings And RFP Momentum Will Offset Margin Concerns
Analysts have trimmed their ICON fair value estimate by about US$0.69 to roughly US$205.69. This reflects expectations of softer revenue growth, thinner margins and a slightly higher discount rate, while still using a somewhat higher future P/E assumption in line with recent price target revisions across the Street.Analiz Güncellemesi • Dec 25
ICLR: Strong Bookings And RFP Momentum Will Support Long Term Upside
We nudge our ICON price target slightly higher to approximately $206.38 from about $206.19, as analysts balance continued concerns around 2026 margin pressure and pricing headwinds with updated post Q3 models and confidence that stronger gross bookings and RFP flow can support a healthier long term growth profile. Analyst Commentary Street research reflects a mixed but generally constructive stance on ICON, with price targets converging around the low to mid $200 range and a split between Hold and Outperform ratings.Analiz Güncellemesi • Dec 11
ICLR: Bookings Momentum Will Offset 2026 Margin And Pricing Headwinds
Analysts have modestly trimmed their blended price target on ICON, reflecting a slightly lower valuation multiple as they balance ongoing concerns about 2026 margin and pricing headwinds, highlighted in recent target cuts such as TD Cowen's move to $172 from $183 and Leerink's to $220 from $235, against still-supportive views on bookings momentum and long term growth prospects. Analyst Commentary Bullish Takeaways Bullish analysts highlight that updated models following Q3 results support modest upside to fair value, even after factoring in near term margin noise.Analiz Güncellemesi • Nov 27
ICLR: Bookings Momentum And Leadership Transition Will Drive Renewed Confidence In 2025
ICON’s analyst price target was revised modestly downward from $208.27 to $206.19, as analysts cited ongoing concerns about margin pressure and potential headwinds for 2026. These concerns were partially tempered by encouraging booking trends and updated financial models following recent quarterly results.Analiz Güncellemesi • Nov 08
ICLR: Operational Resilience And Leadership Transition Will Support Momentum Next Year
The analyst price target for ICON has edged lower by approximately $0.67 to $208.27, as analysts cite ongoing concerns about margin pressure and a slightly more cautious revenue growth outlook. Analyst Commentary Analyst sentiment on ICON remains divided, with both encouraging signals and pressing concerns for investors to consider.Analiz Güncellemesi • Oct 24
Margin Pressures And Partnership Wins Will Shape Next-Year Performance Outlook
The analyst fair value estimate for ICON has been revised downward by approximately $7 to $208.93. Analysts cite ongoing concerns about margin pressure and future revenue growth challenges.Seeking Alpha • Oct 22
ICON: Solid Fundamentals Trump Regulatory Headwinds
Summary In H1 2025, ICON's net book-to-bill ratio dropped to its lowest value since at least 2016. However, this ratio could improve since macroeconomic uncertainty is vanishing. ICON has a repurchase program of $1,000 million underway, which could buy approximately 6.90% of the company's outstanding common shares. Despite the challenging times, ICON is a profitable firm, has low debt, and presents symptoms of undervaluation compared to other CRO companies. Read the full article on Seeking AlphaAnaliz Güncellemesi • Sep 13
Midsized Pharma Partnerships And AI Tools Will Streamline Operations
ICON’s consensus price target has been revised down from $220.40 to $215.67 as analysts express caution over persistent revenue and booking growth risks, customer cancellations, and macro uncertainty, which offset recent partnership gains and stable sector demand. Analyst Commentary Bearish analysts highlighted persistent revenue and EBITDA growth risks in 2026 tied to lower-than-normal book-to-bills (BtBs) and customer cancellations, with consensus estimates seen as too optimistic.Analiz Makalesi • Aug 20
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar
NasdaqGS:ICLR 1 Year Share Price vs Fair Value Explore ICON's Fair Values from the Community and select yours ICON...Analiz Makalesi • Aug 12
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 43%?
Key Insights ICON's estimated fair value is US$280 based on 2 Stage Free Cash Flow to Equity ICON's US$160 share price...Analiz Makalesi • Jul 14
What Is ICON Public Limited Company's (NASDAQ:ICLR) Share Price Doing?
Today we're going to take a look at the well-established ICON Public Limited Company ( NASDAQ:ICLR ). The company's...Analiz Makalesi • May 20
We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Feb 24
ICON: An Excellent Investment Opportunity With Strong Growth Potential
Summary ICON's revenues and net income have increased by 196.06% and 137.71%, respectively, between 2020 and 2024. Even though the CRO market expects a challenging outlook for 2025, in the next 9–10 years, the CRO market expects to grow at a 5.8%-7.42% CAGR. ICON has seen a decline in its non-current bank and loan debts of 36.88% since 2021. Its non-current bank and loan debts accounted for 57.74% of its liabilities in 2021. The price-to-book value of ICON has reached its lowest value in the last ten years. In addition, the EV/EBITDA ratio is close to its minimum value in ten years. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
ICON: A High Probability Of Success In The Uncertain R&D Process
Summary Recent share price weakness is due to temporary headwinds, including client cost-cutting and delays in biotech decision-making, not structural issues in the CRO industry. Long-term prospects remain strong and structural growth drivers are still intact. Short-term headwinds led to attractive valuations, offering a compelling investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
ICON: Disappointing Change In Trajectory (Rating Downgrade)
Summary Due to unforeseen headwinds and weakened growth outlook, ICLR's investment case has changed materially. Issues around capital allocation and a slowdown in reinvestment opportunities tempers the potential for earnings growth and returns on capital. ICLR's valuation multiples have contracted significantly, with EV/EBIT dropping from 42x to 18x since '22. Read the full article on Seeking AlphaSeeking Alpha • Jul 13
ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Summary ICON acquired PRA Health Sciences in a $12B deal in 2020, creating a new company. The stock has doubled since the acquisition, and could be worth $370-$400/share based on earnings estimates and excess earnings above assets of similar price and risk. Its strong order book, earnings leverage, and attractive valuations support a buy recommendation. Read the full article on Seeking AlphaHissedar Getirileri
| ICLR | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 5.6% | 1.8% | 2.1% |
| 1Y | -9.7% | 7.7% | 30.6% |
Getiri vs. Endüstri: ICLR geçen yıl % 7.7 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: ICLR geçen yıl % 30.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ICLR volatility | |
|---|---|
| ICLR Average Weekly Movement | 14.9% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: ICLR hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: ICLR 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 10% dan 15% a yükseldi.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1989 | 39,800 | Barry Balfe | www.iconplc.com |
Bir klinik araştırma kuruluşu olan ICON Public Limited Company, İrlanda'da, Avrupa'nın geri kalanında, Amerika Birleşik Devletleri'nde ve uluslararası alanda dış kaynaklı geliştirme ve ticarileştirme hizmetleri sunmaktadır. Şirket, bileşik seçiminden Faz I-IV klinik çalışmalara kadar klinik geliştirme sürecinin çeşitli aşamalarını destekleyen programların stratejik gelişimi, yönetimi ve analizi konusunda uzmanlaşmıştır. Ayrıca, geliştirmenin tüm aşamaları, onay öncesi ve sonrası, veri çözümleri ve saha ve hasta erişim hizmetleri dahil olmak üzere klinik geliştirme hizmetleri; klinik araştırma yönetimi, danışmanlık ve sözleşmeli personel hizmetleri; ve klinik geliştirme stratejisi, planlama ve deneme tasarımı, tam çalışma yürütme ve pazar sonrası ticarileştirmeyi içeren ticari hizmetler sunmaktadır.
ICON Public Limited Company Temel Bilgiler Özeti
| ICLR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$9.48b |
| Kazançlar(TTM) | US$599.48m |
| Gelir(TTM) | US$8.10b |
15.9x
F/K Oranı1.2x
P/S OranıICLR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ICLR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$8.10b |
| Gelir Maliyeti | US$5.82b |
| Brüt Kâr | US$2.28b |
| Diğer Giderler | US$1.68b |
| Kazançlar | US$599.48m |
Son Raporlanan Kazançlar
Sep 30, 2025
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 7.85 |
| Brüt Marj | 28.15% |
| Net Kâr Marjı | 7.40% |
| Borç/Özkaynak Oranı | 36.5% |
ICLR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/07 18:04 |
| Gün Sonu Hisse Fiyatı | 2026/05/07 00:00 |
| Kazançlar | 2025/09/30 |
| Yıllık Kazançlar | 2024/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ICON Public Limited Company 31 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Eric Coldwell | Baird |
| Douglas Tsao | Barclays |
| Luke Sergott | Barclays |